Clinical trials: Lymphocytic Leukemia
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01474681
- Testing
- HSC835
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family members or unrelated donors with a similar type of bone marrow usually donate their bone marrow to the transplant patients.
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell
- Trial name
- NCT00849147
- Testing
- Haploidentical Bone Marrow Transplantation, GVHD prophylaxis
- Where
- 17 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Leukemia, Lymphocytyc
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are types of blood or lymph node cancers that mostly affect the elderly.
- Conditions
- Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
- Trial name
- NCT01500733
- Testing
- PCI 32765
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
The objectives of Part 1 of the study were: To determine the rate of hematologic response (HR) lasting ≥4 weeks in participants with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the accelerated phase…
- Conditions
- Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT00171249
- Testing
- STI571 400 mg, STI571 600 mg
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well a dose adjusted regimen consisting of etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) works in combination with ofatumumab or rituximab in…
- Conditions
- AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Trial name
- NCT02199184
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Ibrutinib is currently FDA approved and commercially available for the treatment of CLL. However, some researchers think the approved dose may be unnecessarily high.
- Trial name
- NCT02801578
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
This study will test the safety and effectiveness of adding bortezomib and vorinostat to other chemotherapy drugs commonly used to treat relapsed or refractory leukemia.
- Conditions
- Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT02419755
- Testing
- Bortezomib, Vorinostat, Mitoxantrone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Lymphocytic Leukemia, Leukemia
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if lenalidomide (Revlimid®) can help to control CLL in patients who have already received standard therapy. The safety of lenalidomide will also be studied.
- Trial name
- NCT00267059
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large…
- Trial name
- NCT01030536
- Testing
- CAT-8015 20 mcg/kg, CAT-8015 30 mcg/kg, CAT-8015 40 mcg/kg
- Where
- 8 sites in United States, Poland
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia
Sitagliptin Umbilical Cord Blood Transplant Study
The main purpose of this trial is to study whether the drug sitagliptin can be given safely to patients undergoing umbilical cord blood transplantation to speed up engraftment (recovery of blood counts after transplant).
- Conditions
- Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic
- Trial name
- NCT00862719
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Indiana University
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Leukemia, Lymphoblastic, Leukemia
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
To learn if the combination of 2 study drugs, CB-103 and venetoclax, can help to control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients
- Trial name
- NCT05464836
- Testing
- CB-103, Venetoclax
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Large Granular Lymphocytic Leukemia, LGL Leukemia
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
Background: Large granular lymphocyte (LGL) leukemia is a low-grade non-Hodgkin's lymphoma. LGL is associated with low numbers of white blood cells (leading to recurring infections), red blood cells (causing anemia) and platelets…
- Trial name
- NCT00363779
- Testing
- Cyclosporine, Gene expression analysis, Microarray analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
The purpose of this study was to provide the opportunity to the participants who progressed on treatment arm previously in the study UTX-TGR-304 (NCT02612311) to receive ublituximab (TG-1101) treatment in combination with…
- Trial name
- NCT02656303
- Testing
- Ublituximab, Umbralisib
- Where
- 87 sites in United States, Italy and 2 more
- Volunteers
- 116 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
The investigators' hypothesis is that treatment of CLL with an alternating daily dosing schedule of thalidomide and lenalidomide may result in better tolerability by decreasing each agent's individual toxicities, while preserving…
- Trial name
- ThRiL (NCT01125176)
- Testing
- thalidomide, lenalidomide, rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Hepatitis, Safety and Tolerability
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Background: People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune systems are weakened.
- Trial name
- NCT03685708
- Testing
- HEPLISAV-B
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lymphocytic Leukemia
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta…
- Trial name
- NCT02742090
- Testing
- Umbralisib
- Where
- 15 sites in United States
- Volunteers
- 51 people
- Sponsor
- TG Therapeutics, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic…
- Trial name
- ISAKIDS (NCT03860844)
- Testing
- Isatuximab, Dexamethasone or equivalent, Fludarabine
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 67 people
- Sponsor
- Sanofi
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Bridalveil (NCT01732926)
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 144 sites in United States, Australia and 13 more
- Volunteers
- 475 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL.
- Trial name
- NCT02315768
- Testing
- GA101, Ibrutinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego